Organon & Co. (OGN) Competitors

Genmab A/S (NASDAQ:GMAB) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.

Does the MarketBeat Community favor GMAB or OGN?

Genmab A/S received 142 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 62.60% of users gave Genmab A/S an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 159 62.60%	Underperform Votes 95 37.40%
Organon & Co.	Outperform Votes 17 34.00%	Underperform Votes 33 66.00%

Does the media prefer GMAB or OGN?

In the previous week, Organon & Co. had 8 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Organon & Co. and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.57 beat Organon & Co.'s score of 0.33 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	2 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders and institutionals believe in GMAB or OGN?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 1.4% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts prefer GMAB or OGN?

Genmab A/S currently has a consensus price target of $45.20, suggesting a potential upside of 98.42%. Organon & Co. has a consensus price target of $21.33, suggesting a potential upside of 26.08%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genmab A/S is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Organon & Co.	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Is GMAB or OGN more profitable?

Genmab A/S has a net margin of 29.06% compared to Organon & Co.'s net margin of 20.30%. Organon & Co.'s return on equity of 2,437.43% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	29.06%	17.48%	15.13%
Organon & Co.	20.30%	2,437.43%	8.24%

Which has more risk and volatility, GMAB or OGN?

Genmab A/S has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.

Which has higher earnings & valuation, GMAB or OGN?

Organon & Co. has higher revenue and earnings than Genmab A/S. Organon & Co. is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	6.31	$631.91M	$1.21	18.83
Organon & Co.	$6.41B	0.68	$1.02B	$5.04	3.36

Summary

Genmab A/S beats Organon & Co. on 12 of the 19 factors compared between the two stocks.